FDA.reportPublic FDA data

Invokamet XR 150 MG / 500 MG 24HR Extended Release Oral Tablet

RxCUI
1811003
RxNorm name
Invokamet XR 150 MG / 500 MG 24HR Extended Release Oral Tablet
Display name
Invokamet XR 150 MG / 500 MG 24HR Extended Release Oral Tablet
Full name
Invokamet XR 150 MG / 500 MG 24HR Extended Release Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:02

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
INVOKAMETCANAGLIFLOZIN AND METFORMIN HYDROCHLORIDEJanssen Pharmaceuticals, Inc.6868666b-c25e-40d1-9d1f-306bbe9390c12026-08-24Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 1811003

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
6868666b-c25e-40d1-9d1f-306bbe9390c1Invokamet XR 150 MG / 500 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR canagliflozin 150 MG / metformin hydrochloride 500 MG Extended Release Oral Tablet [Invokamet] [SBD] · Invokamet (canagliflozin 150 MG / metformin hydrochloride 500 MG) 24HR Extended Release Oral Tablet [SY]331These highlights do not include all the information needed to use INVOKAMET or INVOKAMET XR safely and effectively. See full prescribing information for INVOKAMET or INVOKAMET XR. INVOKAMET ® (canagliflozin and metformin hydrochloride) tablets, for oral use INVOKAMET ® XR (canagliflozin and metformin hydrochloride) extended-release tablets, for oral use Initial U.S. Approval: 201420250821